Russian Heart Failure Journal 2010year Torasemide - a new generation loop diuretic: main features of pharmacology and clinical effectiveness in patients with heart failure


To access this material please log in or register

Register Authorize
2010/

Torasemide - a new generation loop diuretic: main features of pharmacology and clinical effectiveness in patients with heart failure

Preobragenskiy D. V., Nekrasova N. I., Talyzina I. V., Pataraya S. A.

Keywords: loop diuretics, pharmacology, CHF, efficacy

DOI: 10.18087/rhfj.2010.5.1409

Torasemide is the first representative of a new generation of loop diuretics, which is due to particular pharmacological effects completely different from the first generation of loop diuretics (like furosemide, bumetanide and ethacrynic acid). Medium and high-dose torasemide is used for chronic heart failure treatment, decompensated liver cirrhosis and chronic renal failure. Low-dose torasemide has a long-term antihypertensive effect, slightly affecting potassium blood level and indicators of purine, carbohydrate and lipid metabolism. Due to this features torasemide (in contrast to first-generation loop diuretics) can be used for long-term treatment of arterial hypertension.
  1. Преображенский Д. В., Сидоренко Б. А., Тарыкина Е. В. и др. Торасемид – петлевой диуретик нового поколения: особенности клинической фармакологии и терапевтическое применение. Кардиология. 2006;46 (10):75–86.
  2. Greger RF, Knauf H, Mutschler E. Handbook of experimental pharmaco­logy, Vol. 117, Diuretics, Springer, Berlin, Heidelberg, New York, 1995.
  3. Brater DC. Torasemide. In: Messerli FH, ed. Cardiovascular Drug Therapy. Philadelphia, Pa: WB Saunders Co; 1996. pp. 402–412.
  4. Friedel H, Buckley MM. Torasemide. A review of its pharmacology and therapeutic potential. Drugs. 1991;41 (1):81–103.
  5. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49 (1):121–142.
  6. Bölke T, Achhammer IG: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs of Today. 1994;30:1–8.
  7. Uchida T, Yananaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205 (2):145–150.
  8. Uchida T, Yananaga K, Kido H et al. Diuretic and vasodilating actions of torasemide. Cardiology. 1994;84 (Suppl 2):14–17.
  9. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63 (3):PL45–50.
  10. Fortuno A, Muniz P, Ravassa S et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999;34 (1):138–143.
  11. Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf. 1996;14 (2):104–120.
  12. Puschett JB, Jordan LL. Mode of action of torasemide in man. In: Progress in Pharmacology and Clinical Pharmacology. Ed. By FM Eichelbaum et al. vol. 8. № 1. Stuttgart New York. 1990. pp. 3–13.
  13. Reyes AJ. Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects. Drugs. 1991;41 (Suppl 3):35–59.
  14. Reyes AJ. Renal excretory profiles of loop diuretics: consequences for therapeutic application. J Cardiovascular Pharmacology. 1993;22 (Suppl 3):S11‑S23.
  15. Barr WH, Smith H, Karnes HT et al. Comparison of bioavailability, pharmacokinetics and pharmacodynamics of torasemide in young and elderly healthy volunteers. In: Progress in Pharmacology and Clinical Pharmacology. Ed. By F. M. Eichelbaum et al. vol. 8. № 1. Stuttgart New York. 1990. pp. 15–28.
  16. Brater DC. Pharmacokinetics and pharmacodynamics of torasemide in health and disease. J Cardiovascular Pharmacology. 1993; 22 (Suppl 3):S24‑S31.
  17. Allison ME, Shilliday I. Loop diuretic therapy in acute and chronic renal failure. J Cardiovascular Pharmacology. 1993;22 (Suppl 3):S59‑S70.
  18. Risler T, Kramer B, Muller GA. The efficacy of diuretics in acute and chronic renal failure. Drugs. 1991;41 (Suppl 3):69–79.
  19. Barr WH, Smith H, Karnes HT et al. Torasemide dose-proportionality of pharmacokinetics and pharmacodynamics. In: Progress in Pharmacology and Clinical Pharmacology. Ed. By F. M. Eichelbaum et al. vol. 8. № 1. Stuttgart New York. 1990. pp. 29–37.
  20. von Mollendorff E, Neugebauer G. Pharmacokinetics of oral torasemide in patients with congestive heart failure. In: Progress in Pharmacology and Clinical Pharmacology. Ed. By F. M. Eichelbaum et al. vol. 8. № 1. Stuttgart New York. 1990. pp. 73–79.
  21. Knauf H, Spahn H, Rucker HM, Mutscheler E. The loop diuretic torasemide in renal failure – kinetics and dynamics. In: Progress in Pharmacology and Clinical Pharmacology. Ed. By F. M. Eichelbaum et al. vol. 8. № 1. Stuttgart New York. 1990. pp. 81–93.
  22. Dupont A. G, Gerlo E, van der Niepen P. et al. Renal pharmacodynamic effects of torasemide and furosemide in normal man. Drug. Res. 1988;38 (1):172–175.
  23. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157 (21):2413–2446.
  24. Chobanian AN, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289 (19):2560–2572.
  25. Stauch M, Stiehl L. Controlled, double-blind clinical trial on the efficacy ans tolerance of torasemide in comparison with furosemide in patients with congestive heart failure – a multicenter study. In: Progress in Pharmacology and Clinical Pharmacology. Ed. By F. M. Eichelbaum et al. vol. 8. № 1. Stuttgart New York. 1990. pp. 121–126.
  26. Achhammer I. Long term efficacy and tolerance of torasemide in congestive heart failure. In: Progress in Pharmacology and Clinical Pharmacology. Ed. By F. M. Eichelbaum et al. vol. 8. № 1. Stuttgart New York. 1990. pp. 127–136.
  27. Piesche L, Achhammer I, Glocke M et al. Comparison of torasemide with furosemide in patients with chronic heart failure. In: Diuretics II: chemistry, pharmacology, and clinical applications. Ed. By J. B. Puschett, A. Greenberg. Amsterdam, Elsevier Science Publishers. 1987. pp. 65–67.
  28. Yamato M, Sasaki T, Honda K. et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384–390.
  29. Mizuno Y, Yoshimura M, Yasie H et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103 (1):72–77.
  30. Lopez B, Querejeta R, Sanchez E et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43 (11):2028–2035.
  31. Spannheimer A, Goertz A, Dreckmann-Behrendt B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract. 1998;52 (7):467–471.
  32. Fassbinder W, Achhammer I, Ziegler J. Improved prognosis of patients with chronic heart failure by an optimized diuretic therapy with the new loop diuretic torasemide. J Am Col Cardiol. 1998;31 (Suppl C):Abstr. 1401.
  33. Brater DC. Loop diuretics – translating pharmacokinetic properties into improved clinical outcomes. Eur Heart J. 2001;3 (Suppl G):G19‑G24.
  34. Noe LL, Vreeland MG, Pezzella SM, Trotter JP. A pharmacoeconomic assessment of torasemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther. 1999;21 (5):854–866.
  35. Stroupe KT, Forthofer MM, Brater DC. Murray MD. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17 (5):429–440.
  36. Cosin J, Diez J. Effects of type diuretic on mortality in patients with chro­nic congestive heart failure – benefits and hazards. Eur J Heart Fail. 2000;2 (Suppl 2):P71.
  37. Cosin J, Diez J. Torasemide in chronic heart failure: Results of the TORIC study. Eur J Heart Fail. 2002;4 (4):507–513.
  38. Murray MD, Deer MM, Ferguson JA et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111 (7):513–520.
  39. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26 (11):1115–1140.
  40. ACC / AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in adult – Summary article (A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46 (6):1116–1144.
Preobragenskiy D. V., Nekrasova N. I., Talyzina I. V. et al. Torasemide - a new generation loop diuretic: main features of pharmacology and clinical effectiveness in patients with heart failure. Russian Heart Failure Journal. 2010;11(5):294-300.

To access this material please log in or register

Register Authorize
Ru En